PDA in Premature Babies: Understanding Treatment Options and Outcomes
"A comprehensive look at current strategies for managing Patent Ductus Arteriosus (PDA) in very-low-birth-weight infants in Korea, including treatment options and key considerations for parents and caregivers."
The failure of the ductus arteriosus to close after birth, known as Patent Ductus Arteriosus (PDA), is a common issue in premature infants, particularly those born very prematurely (less than 28 weeks of gestation). PDA can lead to increased mortality and other health problems, including bronchopulmonary dysplasia (BPD), periventricular hemorrhage, and necrotizing enterocolitis (NEC).
Deciding on the best course of treatment for PDA is complicated. There are potential risks associated with both medical treatments and surgical interventions. Therefore, clinicians must carefully consider the benefits and risks of each treatment when making management decisions.
Recent research and clinical trials have not reached a consensus on the best treatment strategies for PDA. This article explores current practices for managing PDA in very-low-birth-weight (VLBW) infants in Korea, based on data from the Korean Neonatal Network (KNN). We'll examine the various treatment approaches and factors influencing those decisions.
Uncertainty and Variation in PDA Care
Treatment strategies for patent ductus arteriosus in extremely preterm infants differ widely. Uncertainty about what constitutes a hemodynamically significant PDA and limited high-quality data on long-term outcomes have contributed to inconsistent management. The American Academy of Pediatrics likewise reports that uncertainty and controversy persist regarding PDA significance, assessment, and management, resulting in substantial variability in clinical practice.
Established Care and Its Limits
The UC Davis NICU guideline states that PDA is commonly observed in extremely preterm infants, with incidence as high as 50%. Reported complications include pulmonary hemorrhage, congestive heart failure, worsening bronchopulmonary dysplasia, and pulmonary hypertension. Despite bedside echocardiography improving understanding of PDA physiology, uncertainty remains about whether and when treatment provides more benefit than harm.
A Longstanding Clinical Debate
Caregivers have debated the significance and treatment of PDA for more than a century. Historical accounts describe continuing disagreement about whether PDA should be treated and, if so, which approach should be used. The history of ductus arteriosus knowledge has been described across overlapping periods, including anatomical observation, early cardiac surgery, and fetal physiology.
What are the Key Treatment Strategies for PDA in Premature Infants?
A study investigated current therapeutic strategies for PDA in very-low-birth-weight (VLBW) infants in Korea. The study included 2,254 VLBW infants from the Korean Neonatal Network cohort born between January 2013 and June 2014. Here's a breakdown of the findings:
- Prophylactic Treatment (PT): Administering treatment to prevent PDA, n = 69, 3.1%.
- Pre-Symptomatic Treatment (PST): Treating PDA based on diagnostic findings before symptoms appear, n = 212, 9.4%.
- Symptomatic Treatment (ST): Treating PDA in response to clinical signs and symptoms, n = 596, 26.4%.
- Conservative Treatment (CT): Providing supportive care without medical or surgical intervention, n = 171, 7.6%.
Findings From the PDA Randomized Trial
In the PDA Randomized Clinical Trial, death before 36 weeks’ postmenstrual age occurred in 4.1% of infants receiving expectant management, compared with 9.6% of infants receiving active treatment. The adjusted risk difference was -5.6%, with a 95% confidence interval of -10.1% to -1.2% and a P value of .01. The trial compared expectant management with active treatment using acetaminophen, ibuprofen, or indomethacin.
Observation Remains Reasonable for Some PDAs
Mayo Clinic reports that some people with small PDAs may need only regular health checkups to monitor for complications. A premature baby with PDA also requires regular follow-up to determine whether the opening closes. For larger untreated PDAs, the organization notes that abnormal blood flow can weaken the heart and contribute to heart failure and other complications, so treatment options may include medicines, a procedure, or surgery.
Benefits of Very Early Drug Treatment
A Cochrane review found that very early drug treatment shortened hospital stays compared with expectant management. Across four studies involving 260 infants, the mean difference was -5.35 days, with a 95% confidence interval from -9.23 to -1.47 days. The evidence for this outcome was rated low certainty, so the estimate should be interpreted cautiously.
What Does This Mean for Parents and Caregivers?
The management of PDA in premature infants is complex, with various treatment strategies available. The decision-making process depends on the baby's gestational age, birthweight, and clinical condition. Further research is needed to standardize treatment guidelines and improve outcomes for preterm infants with PDA.
Medication Closure Rates
A systematic review and meta-analysis evaluated 68 randomized clinical trials involving 4,802 infants. The trials used 14 different variations of indomethacin, ibuprofen, or acetaminophen as treatment modalities. The overall PDA closure rate was 67.4%, representing 2,867 of 4,256 infants with reported closure outcomes.
Demand for PDA Treatment Options
Market Research Future identifies increasing PDA prevalence among neonates and infants as a primary driver of the PDA treatment market. The report states that PDA occurs in approximately 5% to 10% of premature infants. It links this burden to heightened demand for effective treatment options, while broader clinical literature continues to describe PDA as a significant concern across gestational ages.
Risks of Delayed Ductal Closure
Natural closure of the ductus arteriosus is often delayed in premature newborns, particularly in the most immature infants. A substantial left-to-right shunt can raise concerns about pulmonary overcirculation and reduced systemic blood flow. These effects may contribute to neonatal respiratory morbidities such as bronchopulmonary dysplasia.
Progress Toward Less Invasive Closure
The optimal PDA management strategy for extremely premature infants remains unresolved. Percutaneous PDA closure is becoming a standard approach for definitive closure in progressively smaller and younger neonates, and a 2023 study assessed its safety and feasibility in patients weighing 2 kg or less. These developments reflect ongoing efforts to provide definitive treatment while extending options to highly vulnerable infants.